Pharmaceutical company OncoZenge AB (publ) (STO:ONCOZ) announced on Friday plans to partner with Pharmanovia for exclusive commercialization rights of BupiZenge in Europe, the Middle East, and Northern Africa (EMENA).
A non-binding offer has been signed, initiating a period of exclusivity for due diligence and joint planning, with a goal to finalize the agreement by 30 November 2024. The partnership includes potential milestone payments of up to EUR7m to support Phase 3 trials and commercialization. Additional commercial milestone payments and royalties on sales are part of the agreement. Pharmanovia will leverage its regulatory and market expertise to facilitate the clinical program and market entry.
OncoZenge is preparing to appoint a CDMO and begin technology transfer for Phase 3 lozenge production, targeted for early 2025. A CRO will be appointed after the Phase 3 study protocol is finalized. BupiZenge, an oral lozenge of bupivacaine, is aimed at treating oral mucositis, a severe pain condition affecting cancer patients. Phase 2 trials showed significant pain relief compared to the current standard of care.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient